Showing 5531-5540 of 8839 results for "".
- Lumenis Introduces NuEra Tighthttps://practicaldermatology.com/news/lumenis-introduces-nuera-tight/2460502/Lumenis is rolling out the NuEra Tight with FocalRF technology for body contouring. NuEra Tight will be available worldwide starting with the United States in August 2020 and Europe, the Middle East and Asia later this year. "Radio Frequency treatments are among the most
- Laseroptek Introduces Pallas UVB Laser in UShttps://practicaldermatology.com/news/laseroptek-introduces-pallas-uvb-laser-in-us/2460499/South Korea-based Laseroptek Co., Ltd. is launching the Pallas Solid-State 311nm UVB laser for the treatment of vitiligo, psoriasis, atopic dermatitis and leukoderma in the United States. Pallas allows the choice of either 308 or 311 nanomet
- New York’s Mount Sinai Health System Names New Chair of Dermatology and New Dean For Clinical Therapeuticshttps://practicaldermatology.com/news/new-yorks-mount-sinai-health-system-names-new-chair-of-dermatology-and-new-dean-for-clinical-therapeutics/2460486/Emma Guttman-Yassky, MD, PhD, is the new Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Health System. She will be the first woman to serve as Chair of a Department of Dermatology in New York City. S
- Industry Responds to COVID-19: Cyrex Labs Offers Multiple Autoimmune Reactivity Screenhttps://practicaldermatology.com/news/industry-responds-to-covid-19-pyrex-labs-offers-multiple-autoimmune-reactivity-screen/2460484/With the risks associated with COVID-19 and because those with one autoimmune disease have a 25 percent chance of developing another, specialists say it is critical for those with autoimmune disease to use safety measures, good eating habits, and self-care to avoid contracting this or any virus.&
- ISHRS: New Guidelines for Hair Restoration Surgery During COVID-19 Pandemichttps://practicaldermatology.com/news/ishrs-new-guidelines-for-hair-restoration-surgery-during-covid-19-pandemic-1/2460469/Hair restoration surgeries can proceed safely in the midst of the ongoing COVID-19 pandemic, the International Society of Hair Restoration Surgery (ISHRS) says. The organization has established suggested protocols for resuming hair restoration practices and offers patients guidance in f
- Dr. Marilyn Liang Assumes SPD Presidencyhttps://practicaldermatology.com/news/dr-marilyn-liang-assumes-sdp-presidency/2460468/Marilyn Liang, MD is the new president of the
- Arcutis Initiates Patient Enrollment in Phase 2b Study in Chronic Hand Eczemahttps://practicaldermatology.com/news/arcutis-initiates-patient-enrollment-in-phase-2b-study-in-chronic-hand-eczema/2460466/Arcutis Biotherapeutics, Inc. initiated enrollment in the Phase 2b portion of the Phase 1/2b study of ARQ-252, a potent and highly selective topical small molecule inhibitor of Janus kinase type 1 (JAK1), in adult patients with chronic hand eczema. Topline data from this trial are expected in the
- Cutera Launches Fraxis PROhttps://practicaldermatology.com/news/cutera-launches-fraxis-pro/2460464/Cutera, Inc. is launching Fraxis PRO progressive dermal remodeling technology. Fraxis PRO combines fractional CO2 for skin resurfacing and radiofrequency microneedling for dermal remodeling in a single device. Fraxis PRO treats: Fine Lines
- Allergan Helps Bridge the Gender Gap in STEMhttps://practicaldermatology.com/news/allergan-helps-bridge-the-gender-gap-in-stem/2460460/Allergan has pledged $300K to support STEM Education through their partnership with Girls Inc. In addition to the donation, Allergan is also offering mentoring initiatives and resources to educate and emp
- Phase 2 Studies: Revance’s DaxibotulinumtoxinA for Injection Looks Good for Forehead Lines, Crow’s Feethttps://practicaldermatology.com/news/phase-2-studies-revances-daxibotulinumtoxina-for-injection-looks-good-for-forehead-lines-and-crows-feet/2460456/Revance Therapeutics, Inc.’s next-generation neuromodulator product, DaxibotulinumtoxinA, safely and effectively smoothed forehead lines and crow’s feet with a median duration of 27 weeks in forehead lines and 24 weeks in crow’s feet achieved in at least one treatment group